Literature DB >> 25842084

Commentary on the clinical trial reported by: Tewari KS, Sill M, Long III HJ, et al. Incorporation of bevacizumab in the treatment of recurrent and metastatic cervical cancer: a phase III randomized trial of the Gynecologic Oncology Group. J Clin Oncol 2013;(suppl; abstr 3).

Michael L Friedlander1.   

Abstract

Entities:  

Year:  2014        PMID： 25842084     DOI： 10.3978/j.issn.2304-3865.2013.11.01

Source DB:  PubMed          Journal:  Chin Clin Oncol        ISSN： 2304-3865


× No keyword cloud information.
  19 in total

1.  From ASCO-gynaecological cancer: Advances in cervical cancer screening and treatment.

Authors:  Rebecca Kirk
Journal:  Nat Rev Clin Oncol       Date:  2013-06-18       Impact factor: 66.675

2.  The clinical significance of occult gynecologic primary tumours in metastatic cancer.

Authors:  M B Hannouf; E Winquist; S M Mahmud; M Brackstone; S Sarma; G Rodrigues; P K Rogan; J S Hoch; G S Zaric
Journal:  Curr Oncol       Date:  2017-10-25       Impact factor: 3.677

3.  Bevacizumab increases the risk of gastrointestinal perforation in cancer patients: a meta-analysis with a focus on different subgroups.

Authors:  Wei-Xiang Qi; Zan Shen; Li-Na Tang; Yang Yao
Journal:  Eur J Clin Pharmacol       Date:  2014-05-27       Impact factor: 2.953

Review 4.  Patient-derived xenograft models in gynecologic malignancies.

Authors:  Clare L Scott; Helen J Mackay; Paul Haluska
Journal:  Am Soc Clin Oncol Educ Book       Date:  2014

5.  Thirty-minutes infusion rate is safe enough for bevacizumab; no need for initial prolong infusion.

Authors:  Mustafa Teoman Yanmaz; Sebnem Izmır Guner; Bahar Satılmıs; Huseyın Akyol; Mehmet Akıf Aydın
Journal:  Med Oncol       Date:  2014-10-08       Impact factor: 3.064

Review 6.  Influence of tumour micro-environment heterogeneity on therapeutic response.

Authors:  Melissa R Junttila; Frederic J de Sauvage
Journal:  Nature       Date:  2013-09-19       Impact factor: 49.962

7.  The Impact of HPV as an Etiological Factor in Gynecological and Oropharyngeal Cancer.

Authors:  Rafael Mañon; Veronica Schimp; Priya Gopalan; Kavita Pattani; Jennifer Tseng
Journal:  Am J Lifestyle Med       Date:  2015-02-12

8.  Vascular endothelial growth factor (VEGF) targeting therapy for persistent, recurrent, or metastatic cervical cancer.

Authors:  Yunhai Chuai; Ivana Rizzuto; Xia Zhang; Ying Li; Guanghai Dai; Sophie J Otter; Rasiah Bharathan; Alexandra Stewart; Aiming Wang
Journal:  Cochrane Database Syst Rev       Date:  2021-03-04

Review 9.  Functional imaging to predict tumor response in locally advanced cervical cancer.

Authors:  Tara D Barwick; Alexandra Taylor; Andrea Rockall
Journal:  Curr Oncol Rep       Date:  2013-12       Impact factor: 5.075

10.  Genetic variant predicts bevacizumab-induced hypertension in ECOG-5103 and ECOG-2100.

Authors:  B P Schneider; L Li; F Shen; K D Miller; M Radovich; A O'Neill; R J Gray; D Lane; D A Flockhart; G Jiang; Z Wang; D Lai; D Koller; J H Pratt; C T Dang; D Northfelt; E A Perez; T Shenkier; M Cobleigh; M L Smith; E Railey; A Partridge; J Gralow; J Sparano; N E Davidson; T Foroud; G W Sledge
Journal:  Br J Cancer       Date:  2014-08-12       Impact factor: 7.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.